Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q2 2019 · 10-Q
Revenue—
Net Income-$7.44M-$7.44MN/M vs Q2 2018 EPS Diluted-$0.30-$0.30N/M vs Q2 2018 Operating Income-$7,432,000N/M Operating Cash Flowderived-$3,927,800N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Sep 30, 2018 · filed Oct 29, 2018 · 29 d after period end